Gamlen Tablet Press produces model data
Gemlen R-series
Used to demonstrate the use of statistical methodologies of Principal Components Analysis and Design of Experiments.
Gamlen R-series tablet presses have been used to demonstrate the use of statistical methodologies of Principal Components Analysis (PCA) and Design of Experiments (DoE) in a workshop on understanding and optimising chemical processes.
Delivered by the Industrial Statistics Research Unit (ISRU), Newcastle University and the Department of Chemistry, Durham University, the Gamlen R-series (formally the GTP-1) was used during practical sessions to produce tabletability data.
Professor Patrick Steel, Durham University, explains: “As part of the course we conducted a laboratory experiment. One of the problems in creating the course is designing an experiment that will deliver reproducible results so that the students can generate models from the data.
We were keen to choose a chemistry orientated experiment — with tablet making there are a number of variables that can be controlled such as the speed of the press, the composition of the tablet and the compaction force. These are all variables that we could adjust fairly easily in the lab experiment. During trialling, we quickly found that the Gamlen Tablet Press generated very consistent results and allowed control of variables which made the Gamlen R-series an ideal tool to teach the important course principles.
Experiments were conducted repeatedly over the two consecutive days of the course and were found to generate the same data. To get our course objectives across, it was imperative that we could rely on the experiment to work and the Gamlen Tablet Press gave us that reproducibility. If errors occurred, something had gone wrong in the experiment itsel; i.e., errors were errors — not random noise in the data. This was important as it supported the material we were teaching.”
Gamlen R-series tablet presses are easy to use, with novice users requiring as little as 30 minutes training to be able to control the basic functions of the instruments. Ideal for the academic research market, Gamlen R-series machines are entirely computer-controlled, portable, laboratory instruments that enable understanding and experimentation with the relationship between the properties of substances, the composition of a formulation and the manufacturing process.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.